Elanco Receives Usda Approval for Trucan Ultra Civ H3n2/H3n8 (Canine Influenza Vaccine) Bringing to Market A High Standard of Respiratory Protection

Published: 2025-07-09 09:36:27 ET ELAN

Published on 07/09/2025 at 09:36

Elanco Animal Health Incorporated announced the U.S. Department of Agriculture (USDA) has approved TruCan Ultra CIV H3N2/H3N8, a canine influenza vaccine designed to provide broad respiratory disease protection. The approval of TruCan Ultra CIV completes Elanco's Tru Portfolio of comfortable and convenient combination vaccines made with PureFil Technology, an exclusive process for creating highly purified vaccines designed to reduce adverse reactions and deliver better experiences. In Canine Influenza Virus (CIV) studies, TruCan Ultra CIV was shown to be highly effective in protecting dogs' respiratory disease and improving clinical signs: Zero vaccinated dogs developed lung lesions post H3N2 challenge; 100% neutralization of 33 currently circulating CIV field isolates; Proven to reduce viral shedding; Proven safe across multiple breed and ages in field safety study; Respiratory disease outbreaks can be devastating for patients, their families and veterinary clinics, sometimes leading to facility shutdowns and large financial impact.

Canine Infectious Respiratory Disease Complex (CIRDC) is a collection of respiratory diseases of various causative agents, including CIV among others. Certain breeds can be at a higher risk for severe symptoms associated with CIRDC, especially Brachycephalic dogs - dog breeds with short heads, flat faces and snub nose. These highly at-risk breeds, which includes French Bull dogs, Bulldogs, Pugs, Boston Terriers and more, continue to grow in popularity with six of the top 25 breeds in the U.S. being brachycephalic.

Unfortunately, there is a relatively low rate of vaccination for CIV in the U.S. leaving these highly susceptible patients particularly at risk for developing infection when exposed to CIV.8 Patients with the highest risk factors include social dogs, dogs with pre-existing airway disease and those that are unvaccinated or incompletely vaccinated. Elanco's Tru Vaccine line is the first vaccine line recommended by Fear Free®?, an organization whose mission is to prevent and alleviate fear, anxiety and stress in pets by inspiring and educating the people who care for them. The approval of Tru can Ultra CIV is a key addition to completing Elanco's vaccine portfolio by addressing respiratory disease outbreaks.

TruCan Ultra CIV is now available for pre-order and will ship within the next 30 business days.